Results 11 to 20 of about 178,943 (330)

Apolipoprotein A-I mimetics [PDF]

Current Opinion in Lipidology, 2014
To summarize recent publications in the field of apolipoprotein mimetics.Apolipoprotein mimetic peptides continue to show efficacy in a number of animal models of disease and demonstrate properties that make them attractive as potential therapeutic agents. A number of new apolipoprotein mimetics have been described recently.
Reddy, Srinivasa T, Navab, Mohamad, Anantharamaiah, Gattadahalli M, Fogelman, Alan M   +3 more
openaire   +4 more sources

Apolipoprotein A‐I induced amyloidosis [PDF]

FEBS Letters, 1998
Amyloidosis is characterized by extracellular deposits of protein fibrils with a high content of β‐sheets in secondary structure. The protein forms together with proteoglycans amyloid fibrils causing organ damage and serious morbidity. Intact apolipoprotein A‐I (apoA‐I) is an important protein in lipid metabolism regulating the synthesis and catabolism
Genschel, Janine, Haas, Regina, Pröpsting, Marcus J, Schmidt, Hartmut H.-J   +3 more
openaire   +2 more sources

On the Aggregation of Apolipoprotein A-I. [PDF]

Int J Mol Sci, 2022
In vivo, apolipoprotein A-I (ApoA-I) is commonly found together with lipids in so-called lipoprotein particles. The protein has also been associated with several diseases—such as atherosclerosis and amyloidosis—where insoluble aggregates containing ApoA-I are deposited in various organs or arteries.
Frankel R, Sparr E, Linse S.
europepmc   +3 more sources

Apolipoprotein A-I Mimetic Peptides [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
Despite identical amino acid composition, differences in class A amphipathic helical peptides caused by differences in the order of amino acids on the hydrophobic face results in substantial differences in antiinflammatory properties. One of these peptides is an apolipoprotein A-I (apoA-I) mimetic, D-4F.
Mohamad, Navab, G M, Anantharamaiah, Srinivasa T, Reddy, Susan, Hama, Greg, Hough, Victor R, Grijalva, Nicholas, Yu, Benjamin J, Ansell, Geeta, Datta, David W, Garber, Alan M, Fogelman   +10 more
openaire   +2 more sources

Apolipoprotein A-I and Cancer [PDF]

Frontiers in Pharmacology, 2015
High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I), the predominant protein in plasma HDL, have long been the focus of intense studies in the field of atherosclerosis and cardiovascular disease. ApoA-I, in large part, is responsible for HDL assembly and its main atheroprotective function, that of shuttling excess cholesterol from peripheral
Zamanian-Daryoush, Maryam, DiDonato, Joseph A.   +1 more
openaire   +2 more sources

Apolipoprotein A-I mimetic peptides [PDF]

Current Atherosclerosis Reports, 2008
Recent publications reveal the mechanism of action of apolipoprotein A-I (apoA-I) mimetic peptides to be the remarkable binding affinity that oxidized lipids have for these peptides compared with apoA-I. There was no difference in the binding affinity of oxidized lipids or in peptide efficacy in reducing inflammation and atherosclerosis in rabbits ...
Brian J, Van Lenten, Alan C, Wagner, G M, Anantharamaiah, Mohamad, Navab, Srinivasa T, Reddy, Georgette M, Buga, Alan M, Fogelman   +6 more
openaire   +2 more sources

Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk

Brazilian Journal of Pharmaceutical Sciences, 2023
Hypertriglyceridemia is associated with several metabolic diseases. The triglycerides (TG) disrupt the cholesterol reverse transport and contribute to increased levels of low-density lipoprotein (LDL).
Richard Rarison Cavalcante Meneses, Nágila Raquel Teixeira Damasceno, Flávia De Conti Cartolano, Sara Maria Moreira Lima Verde, Letícia Gomes Lira, Mariana Brito Dantas, Glautemberg de Almeida Viana, Mateus Edson da Silva, Ederson Laurindo Holanda de Sousa, Gdayllon Cavalcante Meneses, Jamile Magalhães Ferreira, Tiago Lima Sampaio, Maria Goretti Rodrigues de Queiroz   +12 more
doaj   +1 more source

Transport of apolipoproteins A-I and A-II by human thoracic duct lymph [PDF]

, 1981
The daily transport of human plasma apolipoproteins A-I and A-II, triglyceride, and total cholesterol from the thoracic duct lymph into plasma was measured in 2 subjects before and 3 subjects after renal transplantation. Lymph triglyceride transport was ~
Anderson, DW, Brewer, HB, Bronzert, TJ, Forte, T, Lindgren, FT, Niblack, GD, Schaefer, EJ, Starzl, TE, Zech, LA   +8 more
core   +1 more source

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally[S]

Journal of Lipid Research, 2011
To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice.
Mohamad Navab, Srinivasa T. Reddy, G.M. Anantharamaiah, Satoshi Imaizumi, Greg Hough, Susan Hama, Alan M. Fogelman   +6 more
doaj   +1 more source

The secondary structure of apolipoprotein A-I on 9.6-nm reconstituted high-density lipoprotein determined by EPR spectroscopy. [PDF]

, 2013
Apolipoprotein A-I (ApoA-I) is the major protein component of high-density lipoprotein (HDL), and is critical for maintenance of cholesterol homeostasis.
Borja, Mark S, Budamagunta, Madhu S, Lagerstedt, Jens O, Oda, Michael N, Petrlova, Jitka, Voss, John C   +5 more
core   +1 more source